PB2049: MEXICAN REGISTRY OF MYELOPROLIFERATIVE NEOPLASMS. INITIAL REPORT
Authors: J. A. De La Peña Celaya, A. L. Tapia Enriquez, E. P. Paredes Lozano, R. Bates Martin, A. Villela Peña, O. Teomitzi Sanchez, R. Ovilla Martinez, N. Ramirez Muñiz, A. Cuevas Juarez, A. M. Lopez Flores, J. E. Medina Coral, A. S. Garcia Camacho, C. Garcia Castillo, M. M. Bahena Garcia, H. Romero Rodelo, J. Aguilar Luevano, P. E. Baez Islas, J. L. Alvarez Vera, J. M. Perez Zuñiga, E. Hernandez Ruiz, L. L. Arana Luna, M. E. Espitia Rios, L. Montoya Jimenez, M. Alvarado Ibarra
Journal: HemaSphere (2022)

Background: The abnormal proliferation of one or more myeloid cell lines in peripheral blood gives rise to a heterogeneous group of diseases called myeloproliferative neoplasms (MPN). In Mexico the lack of records prevents knowing the exact incidence of this entities, however there have been some efforts to register, such as the one carried out by Ruiz-Argüelleset al in wich are described 24 patientsof one medical center conluding that these pathologies are a rare condition in the mestizo population of our country. Other works by Martínez-Flores et al in 2016 with 36 patients describe some of the clinical and prognostic implications of the JAK2 mutation in this population. Despite this efforts it is unknown the frequency and impact of these pathologies in our population. Aims: To report the frequency of the myeloproliferative neoplasms in the Mexican population. Methods: Multicenter, retrospective, observational report of myeloproliferative neoplasms in 13 mexican medical centers. The frequencies are expresed in median and porcentages. Results: Eighty-six patients from 12 centers throughout the country were included. The baseline demographic characteristics, health status prior to the begining of symptoms and diagnosis are shown in Table 1. Of the total number of patients, bone marrow biopsy was performed in 76% all assessed by general pathologists, 75% of the centers had mutational tests available for clinical diagnosis, the rest based their protocols on clinical criteria and general studies. Of the baseline characteristics of the disease, the most frequent symptom was asthenia/adynamia (45%), 17% had a history of thrombosis at the time of diagnosis and 20% described bone marrow dysplasia. The most frequent clinical diagnosis according to WHO criteria was essential thrombocythemia (53%) which is not consistent with that described in pathology results where primary myelofibrosis was the most frequent (30%) (Fig.1). Disease progression was reported in 5% of patients (4 patients) and death in 4% (3 patients). The most used treatment was cytoredyuctyve therapy in 54%, follow by JAK inhibitor in 27% cases. A correlation between progression and mortality with the clinical diagnosis, the presence of blasts or dysplasia was sought and no statistical significance was found. Image:Summary/Conclusion: To our knowledge this is the most extensive descriptive report of mieloproliferative neoplasias in our country. The heterogeneity of health systems in our country is reflected in the heterogeneity of the results obtained, the great differences in resources of each medical center complicate objective comparisons in order to correlate events with elements of the disease or patients. Comparative analyzes were carried out with the data obtained, however the number of patients did not allow a robust result. However this report should be understood as a first effort for a much-needed national registry that would be of great importance to homogenize the study and management of this disease in Mexico.